Sanofi (NASDAQ:SNY) Receives Average Rating of “Buy” from Brokerages

Shares of Sanofi (NASDAQ:SNY) have received an average rating of “Buy” from the ten analysts that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $62.6667.

Several equities research analysts have recently commented on SNY shares. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Barclays reissued an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. Finally, Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $56.00 to $58.00 in a report on Monday, September 8th.

Institutional Investors Weigh In On Sanofi

Several hedge funds have recently added to or reduced their stakes in the business. Cardinal Capital Management raised its stake in shares of Sanofi by 0.3% in the first quarter. Cardinal Capital Management now owns 69,004 shares of the company’s stock worth $3,827,000 after purchasing an additional 199 shares during the last quarter. Perigon Wealth Management LLC raised its stake in shares of Sanofi by 3.1% in the first quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company’s stock worth $367,000 after purchasing an additional 201 shares during the last quarter. Capital Analysts LLC raised its stake in shares of Sanofi by 14.0% in the first quarter. Capital Analysts LLC now owns 1,664 shares of the company’s stock worth $92,000 after purchasing an additional 204 shares during the last quarter. Thomasville National Bank grew its holdings in shares of Sanofi by 0.3% in the second quarter. Thomasville National Bank now owns 80,440 shares of the company’s stock worth $3,886,000 after acquiring an additional 211 shares during the period. Finally, Patriot Financial Group Insurance Agency LLC grew its holdings in shares of Sanofi by 1.0% in the first quarter. Patriot Financial Group Insurance Agency LLC now owns 24,114 shares of the company’s stock worth $1,337,000 after acquiring an additional 232 shares during the period. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Trading Up 1.5%

NASDAQ:SNY opened at $48.80 on Tuesday. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The business has a 50 day moving average price of $48.29 and a two-hundred day moving average price of $49.70. The company has a market cap of $119.83 billion, a P/E ratio of 11.73, a price-to-earnings-growth ratio of 1.17 and a beta of 0.51.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). The company had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The company’s quarterly revenue was down 7.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.73 EPS. As a group, analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.